219 related articles for article (PubMed ID: 30121123)
1. Update on the ECG component of the CiPA initiative.
Vicente J
J Electrocardiol; 2018; 51(6S):S98-S102. PubMed ID: 30121123
[TBL] [Abstract][Full Text] [Related]
2. Electrocardiographic biomarkers to confirm drug's electrophysiological effects used for proarrhythmic risk prediction under CiPA.
Vicente J; Hosseini M; Johannesen L; Strauss DG
J Electrocardiol; 2017; 50(6):808-813. PubMed ID: 28928044
[TBL] [Abstract][Full Text] [Related]
3. Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Vicente J; Johannesen L; Hosseini M; Mason JW; Sager PT; Pueyo E; Strauss DG
PLoS One; 2016; 11(12):e0163619. PubMed ID: 28036334
[TBL] [Abstract][Full Text] [Related]
4. Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs.
Vicente J; Stockbridge N; Strauss DG
J Electrocardiol; 2016; 49(6):837-842. PubMed ID: 27524478
[TBL] [Abstract][Full Text] [Related]
5. Automated Algorithm for J-Tpeak and Tpeak-Tend Assessment of Drug-Induced Proarrhythmia Risk.
Johannesen L; Vicente J; Hosseini M; Strauss DG
PLoS One; 2016; 11(12):e0166925. PubMed ID: 28036330
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Multi-Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study.
Vicente J; Zusterzeel R; Johannesen L; Ochoa-Jimenez R; Mason JW; Sanabria C; Kemp S; Sager PT; Patel V; Matta MK; Liu J; Florian J; Garnett C; Stockbridge N; Strauss DG
Clin Pharmacol Ther; 2019 Apr; 105(4):943-953. PubMed ID: 30447156
[TBL] [Abstract][Full Text] [Related]
7. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
Colatsky T; Fermini B; Gintant G; Pierson JB; Sager P; Sekino Y; Strauss DG; Stockbridge N
J Pharmacol Toxicol Methods; 2016; 81():15-20. PubMed ID: 27282641
[TBL] [Abstract][Full Text] [Related]
8. Cardiologist's point of view: Novel ECG biomarkers and in silico models for proarrhythmic risk prediction: Are we ready?
Mason JW
J Electrocardiol; 2017; 50(6):825-827. PubMed ID: 28919218
[TBL] [Abstract][Full Text] [Related]
9. Differentiating multichannel block on the guinea pig ECG: Use of T
Skinner M; Hale E; Ceuppens P; Pollard C
J Pharmacol Toxicol Methods; 2021; 111():107085. PubMed ID: 34182121
[TBL] [Abstract][Full Text] [Related]
10. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of multiple algorithms for the measurement of the heart rate corrected JTpeak interval.
Couderc JP; Ma S; Page A; Besaw C; Xia J; Chiu WB; de Bie J; Vicente J; Vaglio M; Badilini F; Babaeizadeh S; Chien CS; Baumert M
J Electrocardiol; 2017; 50(6):769-775. PubMed ID: 29021091
[TBL] [Abstract][Full Text] [Related]
12. CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion.
Wallis R; Benson C; Darpo B; Gintant G; Kanda Y; Prasad K; Strauss DG; Valentin JP
J Pharmacol Toxicol Methods; 2018; 93():15-25. PubMed ID: 29958940
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.
Crumb WJ; Vicente J; Johannesen L; Strauss DG
J Pharmacol Toxicol Methods; 2016; 81():251-62. PubMed ID: 27060526
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs.
Koshman YE; Wilsey AS; Bird BM; Endemann AL; Sadilek S; Treadway J; Martin RL; Polakowski JS; Gintant GA; Mittelstadt SW
J Pharmacol Toxicol Methods; 2020; 103():106871. PubMed ID: 32360993
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the "CiPA" Initiative and Design of a Prospective Clinical Validation Study.
Vicente J; Zusterzeel R; Johannesen L; Mason J; Sager P; Patel V; Matta MK; Li Z; Liu J; Garnett C; Stockbridge N; Zineh I; Strauss DG
Clin Pharmacol Ther; 2018 Jan; 103(1):54-66. PubMed ID: 28986934
[TBL] [Abstract][Full Text] [Related]
16. Measurement of J-T
Goto A; Hagiwara-Nagasawa M; Kambayashi R; Chiba K; Izumi-Nakaseko H; Naito AT; Kanda Y; Sugiyama A
Cardiovasc Toxicol; 2019 Aug; 19(4):357-364. PubMed ID: 30712162
[TBL] [Abstract][Full Text] [Related]
17. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
[TBL] [Abstract][Full Text] [Related]
18. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
19. Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice.
Authier S; Pugsley MK; Koerner JE; Fermini B; Redfern WS; Valentin JP; Vargas HM; Leishman DJ; Correll K; Curtis MJ
J Pharmacol Toxicol Methods; 2017 Jul; 86():34-43. PubMed ID: 28223123
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting.
Strauss DG; Gintant G; Li Z; Wu W; Blinova K; Vicente J; Turner JR; Sager PT
Ther Innov Regul Sci; 2019 Jul; 53(4):519-525. PubMed ID: 30157676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
